Aa
Promethera Biosciences raises funds for liver disease therapies
Googling found this article interesting,
Promethera Biosciences raises funds for liver disease therapies
Promethera Biosciences, (Mont-Saint-Guibert, Belgium) a cell therapy company operating in the field of liver diseases, has completed an exceptional second round fundraising that generated EUR 23.6 million, including EUR 17 million in capital. Among the new investors are the venture arms of pharmaceutical industry leaders Boehringer Ingelheim and Shire, Japanese investment fund Mitsui Global Investment, US company ATMI and Belgian venture capital fund Sambrinvest. This followed GMP accreditation after successful transfer and scaling up of a production process developed at Université Catholique de Louvain (UCL) into a larger-scale pharmaceutical operation. The company has been granted authorisations from the respective agencies to start its phase I/II clinical study in Belgium and the UK for its HepaStem cell therapeutic product, which may hold a cure for liver diseases and for repairing severe liver defects. The major innovation of Promethera HepaStem resides in the simplicity of the treatment - a simple injection into the vein leading to the liver – which may make it possible to avoid radical and invasive surgery such as a liver transplant.
The five new investors join lead investor Vesalius Biocapital and others from the first-round funding which raised EUR 5.3 million (October 2009). In addition, the Walloon region, which has backed the project since its inception, has granted a loan of EUR 6.6 million to support the clinical development of the HepaStem product.
"We are delighted at the trust our investors have placed in us and the opportunity to successfully complete this exceptional fundraising drive in the current economic context," comments Eric Halioua, CEO of Promethera Biosciences. "Achieving all our objectives a year ahead of plan, the quality of the team, the attractiveness of the company's business model and the proof of concept obtained in humans have been key factors in our investors' decision."
Promethera Biosciences raises funds for liver disease therapies
Promethera Biosciences, (Mont-Saint-Guibert, Belgium) a cell therapy company operating in the field of liver diseases, has completed an exceptional second round fundraising that generated EUR 23.6 million, including EUR 17 million in capital. Among the new investors are the venture arms of pharmaceutical industry leaders Boehringer Ingelheim and Shire, Japanese investment fund Mitsui Global Investment, US company ATMI and Belgian venture capital fund Sambrinvest. This followed GMP accreditation after successful transfer and scaling up of a production process developed at Université Catholique de Louvain (UCL) into a larger-scale pharmaceutical operation. The company has been granted authorisations from the respective agencies to start its phase I/II clinical study in Belgium and the UK for its HepaStem cell therapeutic product, which may hold a cure for liver diseases and for repairing severe liver defects. The major innovation of Promethera HepaStem resides in the simplicity of the treatment - a simple injection into the vein leading to the liver – which may make it possible to avoid radical and invasive surgery such as a liver transplant.
The five new investors join lead investor Vesalius Biocapital and others from the first-round funding which raised EUR 5.3 million (October 2009). In addition, the Walloon region, which has backed the project since its inception, has granted a loan of EUR 6.6 million to support the clinical development of the HepaStem product.
"We are delighted at the trust our investors have placed in us and the opportunity to successfully complete this exceptional fundraising drive in the current economic context," comments Eric Halioua, CEO of Promethera Biosciences. "Achieving all our objectives a year ahead of plan, the quality of the team, the attractiveness of the company's business model and the proof of concept obtained in humans have been key factors in our investors' decision."
i d not give money, sorry but cancer and hiv funds are an example about how to stell money with no results and i d not do this simply because where stem cell was not blocked on humans we have already therapies decades ahead of us
there is a lot of scum on stemcell but emcell in kiev was used for dr bradstreet studies on austism and they are reliable.
Would be interesting to know which liver diseases are considered in the clinical trials. From its website, it seems its application in the area of Hepatitis B concerns acute hepatitis and fibrosis. But what about the rejection problem, since it is basically foreign liver tissue transplant?
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
